{
    "nct_id": "NCT05471856",
    "official_title": "Phase Ia, First in Human Open Label Dose Escalation Trial Evaluating Intravenous BI 1703880 in Combination With Intravenous Ezabenlimab for Treatment of Advanced Solid Tumours",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of an advanced, unresectable and/or metastatic or relapsed/refractory solid tumour. Patient must have at least one measurable lesion (according to Response Criteria in Solid Tumours (RECIST 1.1)).\n* Patient must have exhausted or refused established treatment options for the malignant disease, or is not eligible for established treatment options.\n* Has a lesion amenable to pre-treatment and on-treatment biopsy and patient consents to both biopsies.\n* Medically fit and willing to undergo all mandatory trial procedures.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Adequate organ function or bone marrow reserve as demonstrated at screening by the following laboratory values:\n\n  * Absolute neutrophil count ≥ 1.5x10^9/L (≥ 1.5x10^3/μL, ≥ 1500/mm3); platelet count ≥ 100x10^9/L (≥ 100x10^3/μL, ≥ 100x10^3/mm3), without the use of hematopoietic growth factors within 4 weeks of start of trial medication\n  * Haemoglobin ≥ 90 g/L (≥ 9.0 g/dL, ≥ 5.6 mmol/L)\n  * Estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73m^2 (as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)\n  * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN if no demonstrable liver metastases, or otherwise ≤ 5 x ULN if transaminase elevation is attributable to liver metastases.\n  * Total bilirubin ≤ 1.5 x ULN, except for patients with Gilbert's syndrome: total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN\n  * partial thromboplastin time (PTT) / activated partial thromboplastin time (aPTT) <1.5 x ULN\n* Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the informed consent form (ICF).\n* Signed and dated written ICF in accordance with International Council for Harmonisation- Good Clinical Practice (ICH-GCP) and local legislation, obtained before performing any protocol related procedures that are not part of normal standard of practice care. Note: If a patient declines to participate in the voluntary biobanking component of the trial, he/she will not be excluded from other aspects of the trial.\n\nFurther inclusion criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any investigational or antitumour treatment within 4 weeks or 5 half-life periods prior to the first treatment whichever is shorter.\n* Prior STING agonist therapy.\n* Prior intolerability of a anti-programmed cell death protein 1 (PD-1) or anti-programmed cell death ligand 1 (PD-L1) therapy.\n* History of allergy or hypersensitivity to study agent components.\n* Immunosuppressive therapies including, but not limited to, systemic corticosteroids at doses exceeding >10 mg/day of prednisone or equivalent, and tumour necrosis factor-alpha blockers.\n* Persistent toxicity from previous treatments (including immune related Adverse Events (irAEs)) that has not resolved to Grade ≤1, except for alopecia, xerostomia, and immunotherapy related endocrinopathies.\n* Evidence of active, non-treatment related autoimmune disease, except for endocrinopathies.\n* History or complication of pneumonitis or interstitial lung disease within the last 12 months, or any prior pneumonitis related to immunotherapy.\n\nFurther exclusion criteria apply",
    "miscellaneous_criteria": ""
}